« Return to News | Awards & Advancement

VisionCare closes financing, makes board changes

Tuesday, January 24, 2012 12:51 PM

VisionCare Ophthalmic Technologies, a developer of advanced visual prosthetic devices, will close a Series E financing with Agate Medical Investments leading the expansion round.  Agate's managing general partner, Chanan Schneider, will join the VisionCare team as a board observer.

Allen W. Hill, VisionCare's CEO, said the financing will accelerate the commercial launch of its telescope implant for treating end-stage macular degeneration.

Schneider, managing general partner of Agate, previously was CEO of Beta-O2, a bio-device company, and managing director at Discount Capital Markets, where he led medtech and other technology investments.  

VisionCare also has added two new members to its board of directors: David Israeli, M.D., Pitango Venture Capital, and Yuval Avni, M.D., Giza Venture Capital.

Israeli joined Pitango in 2010 as a venture partner in the life sciences team, focusing on the medical device and biopharmaceuticals sectors. Previously, Israeli held positions at Medtronic and Rythmia Medical.

Avni is a partner at Giza Venture Capital, focusing on investments in life science and cleantech sectors. He is a medical practitioner with clinical experience in general and vascular surgery, and conducted clinical research in human genetics prior to entering the venture capital field.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.